一线PD-1抑制剂组合治疗晚期胆管癌患者:一项回顾性现实研究
Ziqi Ye1, Yanfang Zhang2, Jie Chen3
1Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
International immunopharmacology
|May 28, 2023
概括
一线编程细胞死亡蛋白-1 (PD-1) 抑制剂组合疗法对晚期胆管癌 (CCA) 呈现有前途,在现实环境中提供可管理的不良事件和改善的生存结果.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 胃肠道瘤学 胃肠道瘤学
背景情况:
- 晚期胆管癌 (CCA) 治疗通常涉及组合治疗与编程细胞死亡蛋白-1 (PD-1) 抑制剂.
- 关于CCA这种一线治疗方法的有效性和安全性的现实数据有限.
- 这项研究评估了PD-1抑制剂联合治疗对晚期CCA患者存活时间的影响.
研究的目的:
- 评估一线PD-1抑制剂联合治疗在先进的CCA中的有效性.
- 评估这种治疗策略的安全性和不良事件概况.
- 为了确定治疗反应的潜在预测因素.
主要方法:
- 对接受一线PD-1抑制剂联合治疗的54名晚期CCA患者的回顾性分析.
- 卡普兰-梅尔和Log-Rank方法用于分析无进展生存率 (PFS) 和总生存率 (OS).
- 不良事件 (AE) 和与免疫相关的不良事件 (irAEs) 被系统地记录和分类.
主要成果:
- 中位数PFS为6.6个月,中位数OS为13.9个月.
- 目标应答率 (ORR) 为16.7%,疾病控制率 (DCR) 为79.6%.
- 88.9%的患者经历了AEs,其中37.0%的AEs等级≥3. 常见的3级以上的副作用包括中性质衰竭,贫血和血小板衰竭. 51.9%的人经历了irrAEs,皮疹,甲状腺功能低下和是最常见的. 较低的基线CEA水平与改善的PFS和OS相关.
结论:
- 第一线PD-1抑制剂组合疗法在先进的CCA中显示出有前途的疗效.
- 该疗法显示出可管理的安全性概况,具有可观的AE和irAE发病率.
- 基线CEA水平可以作为预测性生物标志物,用于预先CCA的治疗反应.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Chronic Pancreatitis II: Collaborative Care
117
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
117


